Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...
Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
NORTHAMPTON, MA / / February 27, 2025 / In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income countries, this number ...
NORTHAMPTON, MA / ACCESS Newswire / February 27, 2025 / In high-income countries, more than 80% of children diagnosed with ...
We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...
Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...
The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback